Abbott Laboratories (NYSE:ABT) Now Covered by Analysts at Barclays

by · The Cerbat Gem

Analysts at Barclays started coverage on shares of Abbott Laboratories (NYSE:ABT – Get Free Report) in a research note issued to investors on Wednesday, Benzinga reports. The brokerage set an “overweight” rating and a $120.00 price target on the healthcare product maker’s stock. Barclays‘s price target suggests a potential upside of 22.27% from the company’s current price.

ABT has been the topic of several other research reports. Wells Fargo & Company lifted their target price on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. TD Cowen reiterated a “buy” rating and issued a $135.00 target price on shares of Abbott Laboratories in a research note on Tuesday, September 8th. Piper Sandler restated an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Rothschild & Co Redburn raised Abbott Laboratories from a “neutral” rating to a “buy” rating and increased their price objective for the company from $119.00 to $127.00 in a research report on Friday, October 2nd. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $118.88.

Get Our Latest Stock Report on ABT

Abbott Laboratories Stock Performance

ABT stock opened at $98.14 on Wednesday. The company has a 50-day simple moving average of $106.71 and a 200 day simple moving average of $98.45. The company has a market capitalization of $169.82 billion, a P/E ratio of 31.76, a PEG ratio of 1.86 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $135.13.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same period in the prior year, the business posted $1.26 EPS. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Institutional Trading of Abbott Laboratories

Several hedge funds have recently modified their holdings of the stock. Juncture Wealth Strategies LLC bought a new position in Abbott Laboratories in the 3rd quarter worth approximately $658,000. Congress Asset Management Co. bought a new position in Abbott Laboratories in the 3rd quarter valued at $208,000. Moody National Bank Trust Division increased its stake in shares of Abbott Laboratories by 35.3% in the 3rd quarter. Moody National Bank Trust Division now owns 20,659 shares of the healthcare product maker’s stock valued at $2,042,000 after buying an additional 5,387 shares during the period. Iowa State Bank raised its position in shares of Abbott Laboratories by 10.8% during the third quarter. Iowa State Bank now owns 18,491 shares of the healthcare product maker’s stock worth $1,827,000 after acquiring an additional 1,809 shares during the last quarter. Finally, Legacy Private Trust Co. lifted its stake in shares of Abbott Laboratories by 3.0% during the third quarter. Legacy Private Trust Co. now owns 26,104 shares of the healthcare product maker’s stock valued at $2,580,000 after acquiring an additional 749 shares during the period. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Company Profile

(Get Free Report)

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.

Further Reading